ERBB2 and breast carcinoma: ErbB2 is an orphan growth factor receptor that facilitates breast carcinogenesis: ~ 20% of human breast cancers show overexpression or gene amplification of ErbB2, and targeted treatment—e.g., with the functional monoclonal antibody trastuzumab—improves the prognosis [11].